Clinical Care Options Breast Cancer This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

HER2 Testing and Current Knowledge on the Biology of HER2-Positive Tumors
CCO Slideset - In this downloadable slideset Michael F. Press, MD, PhD provides insight on interpreting HER2 pathology results and how to apply these insights to guide treatment decisions (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research

AZURE Biomarker Subanalysis: Vitamin D Levels, but Not Biomarkers of Bone Turnover, Associated With Risk of Relapse in Early Breast Cancer
Capsule Summary - Specific biomarkers of bone turnover (PINP and CTX) were not associated with disease outcomes in early breast cancer, but sufficient vitamin D levels were associated with a better prognosis and, in postmenopausal women, predictive of zoledronic acid benefit. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research

Challenges With Bone-Modifying Therapy for the Prevention of Skeletal-Related Events
CCO Slideset - Alison T. Stopeck, MD, provides updates and analyses of recent data on the use of bone-targeting agents for the prevention of skeletal-related events in patients with breast cancer. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research

Should Bone-Modifying Agents Be Used as Part of Adjuvant Therapy to Prevent Disease Recurrence?
CCO Slideset - Robert E. Coleman, MD, FRCP, provides updates and analyses of recent data on the use of bone-targeting agents in patients with breast cancer for the prevention of disease recurrence. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research

Challenges With Preventing and Treating Cancer Therapy–Induced Bone Loss
CCO Slideset - Julie R. Gralow, MD, provides updates and analyses of recent data on the use of bone-targeting agents in patients with breast cancer for the prevention of cancer therapy-induced bone loss. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 10, 2012 Category: Cancer & Oncology Source Type: research

Study 301: No OS or PFS Improvement With Eribulin vs Capecitabine in Previously Treated Locally Advanced or Metastatic Breast Cancer
Capsule Summary - Although OS, PFS, and ORR were similar after treatment with eribulin or capecitabine in women with pretreated locally advanced or metastatic breast cancer from Study 301, those with triple-negative, ER-negative, or HER2-negative tumors may benefit more from eribulin. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 9, 2012 Category: Cancer & Oncology Source Type: research

High EGFR Expression Associated With Decreased Adjuvant Trastuzumab Benefit in Some Patients With HER2+ Invasive Breast Cancer
Capsule Summary - EGFR expression over 13 ng/µg as measured by a novel antibody-based quantitative immunofluorescence tissue microarray negatively affected the clinical benefit of trastuzumab given concurrently (as opposed to sequentially) with chemotherapy in a cohort of patients from the NCCTG N9831 trial. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 9, 2012 Category: Cancer & Oncology Source Type: research

PHARE Trial Fails to Show Noninferiority of 6 Months Trastuzumab to 12 Months, in the adjuvant treatment of Early Breast Cancer
Capsule Summary - Additional findings suggest that patients with ER-negative tumors receiving trastuzumab for 12 vs 6 months after adjuvant chemotherapy showed a marked improvement in DFS. (Source: Clinical Care Options Oncology - Breast Cancer)
Source: Clinical Care Options Oncology - Breast Cancer - December 9, 2012 Category: Cancer & Oncology Source Type: research